Key regions: Australia, Japan, United States, Germany, Europe
The Anti-Coagulants market in Chad is showing promising growth in recent years.
Customer preferences: Chadian customers show a preference for Anti-Coagulants that are affordable and easily accessible. Due to the high cost of healthcare, especially for chronic illnesses, many customers opt for generic versions of the medication. Furthermore, customers tend to rely on traditional medicine and only turn to pharmaceutical drugs when the traditional methods fail.
Trends in the market: The Anti-Coagulants market in Chad has seen a steady increase in demand due to the rise in chronic diseases such as cardiovascular diseases and diabetes. The aging population has also contributed to the growth of the market as the risk of developing these diseases increases with age. Additionally, the government has made efforts to improve the healthcare system by increasing the number of healthcare facilities and training medical professionals, which has led to an increase in demand for Anti-Coagulants.
Local special circumstances: Chad faces several challenges in the healthcare sector, including a shortage of medical professionals, inadequate healthcare facilities, and limited access to medication. The country heavily relies on foreign aid for its healthcare system, and the government has limited resources to allocate to the sector. The political instability and conflicts in the country have also affected the healthcare system, making it difficult to provide adequate care to the population.
Underlying macroeconomic factors: Chad is one of the poorest countries in the world, with a large portion of the population living below the poverty line. The country heavily relies on its oil exports, which account for the majority of its GDP. However, the fluctuation in oil prices has had a significant impact on the economy, leading to a decrease in government revenue and limited resources to allocate to the healthcare sector.In conclusion, the Anti-Coagulants market in Chad is developing due to the rise in chronic diseases, the aging population, and the government's efforts to improve the healthcare system. However, the country's limited resources, political instability, and reliance on foreign aid pose significant challenges to the sector's growth.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
